RNS & Investor News
Launch of weight management products in Australia and New Zealand
12 October 2020
Shakes and bars containing OptiBiome® technology
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare,announces the launch of meal replacement shakes and bars containing OptiBiotix's OptiBiome® proprietary weight management technology under the Optislim®brand with Woolworths, ChemistWarehouse and on OptiPharm Pty Ltd's ("OptiPharm") online store in Australia and New Zealand.
These simultaneous launches build on a licence agreement entered into in March 2020 grant ing OptiPharm exclusive use of the OptiBiome® trademark in Australia, parts of Asia, New Zealand, Middle East, the Gulf States and North America (RNS: 31 March 2020) and subsequent extension of terms to include Europe (RNS: 5 August 2020).
OptiPharm is a privately owned Australian company which has been operating for 24 years. OptiPharm's flagship brand , Optislim® , is the No. 1 Australian weight management brand incorporating shakes, soups and bars available as total (very low calorie diet) or partial (low calorie diet) meal replacements.
Garry McDonald, Managing Director of OptiPharm, commented: "We are delighted to announce the release of our Optislim®- Optibiome®range of meal replacement shakes & snack bars. Products will be available to Australian consumers from the week commencing 12 October 2020 via the Chemist Warehouse group and the Woolworths supermarket chain. Release will follow shortly throughout New Zealand with contracts currently being finalised for a number of regions throughout Asia. Essentially, we are revolutionising meal replacements utilising OptiBiome®, the award winning, patented ingredient from OptiBiotix. We look forward to a long and successful association with the OptiBiotix team."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division , commented: "We are very pleased to announce the commercial launch of these weight management products containing OptiBiome® under OptiPharm's Optislim ® brand. OptiBiotix's partnership with Australia's No. 1 weight management brand combined with the retailers' distribution network allows the Company to access a wide base of customers in Australia and New Zealand and provide them with a scientifically proven and award-winning ingredient to help them achieve their weight loss. This first commercial step with OptiPharm highlights the strength of the relationship between the two companies and we look forward to future commercial launches beyond Australia and New Zealand."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR Ltd
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements, and health snacks and food products. The Company's current areas of focus include obesity, digestive health, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiﬁed by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reﬂect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020